UBS Group AG Has $2.72 Million Stock Position in Heron Therapeutics, Inc. $HRTX

UBS Group AG trimmed its position in Heron Therapeutics, Inc. (NASDAQ:HRTX) by 28.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,091,669 shares of the biotechnology company’s stock after selling 842,412 shares during the quarter. UBS Group AG owned approximately 1.14% of Heron Therapeutics worth $2,719,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in HRTX. SG Americas Securities LLC lifted its stake in Heron Therapeutics by 39.1% in the 4th quarter. SG Americas Securities LLC now owns 24,377 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 6,858 shares in the last quarter. The Manufacturers Life Insurance Company lifted its stake in Heron Therapeutics by 5.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 241,048 shares of the biotechnology company’s stock valued at $499,000 after acquiring an additional 11,716 shares in the last quarter. B. Riley Wealth Advisors Inc. bought a new stake in Heron Therapeutics in the 2nd quarter valued at approximately $26,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Heron Therapeutics by 19.3% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 83,756 shares of the biotechnology company’s stock valued at $173,000 after acquiring an additional 13,544 shares in the last quarter. Finally, Orchard Capital Management LLC lifted its stake in Heron Therapeutics by 2.6% in the 3rd quarter. Orchard Capital Management LLC now owns 677,290 shares of the biotechnology company’s stock valued at $853,000 after acquiring an additional 17,357 shares in the last quarter. 80.01% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have commented on HRTX. Wall Street Zen cut Heron Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Zacks Research cut Heron Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Monday, April 27th. Weiss Ratings restated a “sell (e+)” rating on shares of Heron Therapeutics in a research note on Tuesday, April 21st. Finally, HC Wainwright restated a “buy” rating on shares of Heron Therapeutics in a research note on Monday, May 11th. Three analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $4.50.

Heron Therapeutics Trading Up 2.9%

Shares of Heron Therapeutics stock opened at $0.88 on Wednesday. Heron Therapeutics, Inc. has a 12-month low of $0.74 and a 12-month high of $2.30. The stock has a market cap of $167.19 million, a P/E ratio of -4.91 and a beta of 1.70. The company has a quick ratio of 1.51, a current ratio of 2.53 and a debt-to-equity ratio of 17.51. The business’s 50 day moving average is $0.93 and its 200-day moving average is $1.13.

Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings data on Monday, May 11th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.01). Heron Therapeutics had a negative return on equity of 7,747.30% and a negative net margin of 20.53%.The company had revenue of $34.71 million for the quarter, compared to the consensus estimate of $36.72 million. Equities research analysts predict that Heron Therapeutics, Inc. will post -0.05 earnings per share for the current fiscal year.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.

Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.